Effectiveness of an Online Self-management Intervention for Type 2 Diabetes Mellitus (OnSeT-2D)

Gaia AG

Status: Withdrawn

Conditions: Type 2 Diabetes

Treatments: Other: treatment as usual; Behavioral: covivio (additional to treatment as usual)

Study type: Interventional

Funder types: Industry

Identifiers

NCT05525117

covivio trial 2022

Details and patient eligibility

About

This trial was designed to evaluate the effectiveness of the dialogue-based online intervention covivio, which was designed to improve diabetes self-management in patients with type 2 diabetes.

The study aims to test the hypothesis that covivio has a greater positive impact on glycemic control than treatment as usual. Patients with type 2 diabetes mellitus will be randomized and allocated to either an intervention group, receiving covivio in addition to treatment as usual, or a control group, which receives only treatment as usual. The primary endpoint is the HbA1c value six month after baseline.

Full description

The aim of this clinical trial is to investigate the effectiveness of the self-guided digital therapeutic covivio in 268 patients with type 2 diabetes mellitus (T2DM). Patients will be randomized and allocated in a 1:1 ratio to either an intervention group, in which they will receive access to covivio in addition to treatment as usual (TAU, n = 134), or to a control group, in which they will receive only TAU (n = 134).

The primary endpoint of this trial will be the between-groups difference of the HbA1c in the intervention and control group at six months adjusted for the baseline HbA1c. In order to show the course of change over time, two timepoints for assessment of effects are planned at four (T1) and six months (T2) after the baseline assessment (T0). The primary endpoint will be the HbA1c at six months post-allocation. Secondary endpoints will be depression, diabetes self-management (DSM), BMI, and quality of life. Figure 1 (section 6.1) summarizes the design of the clinical trial.

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosis of T2DM (submission of a medical certificate attesting to the presence of at least one of the following ICD-10-GM diagnoses of T2DM: E11.20, E11.30, E11.40, E11.50, E11.60, E11.72, E11.74, E11.80, E11.90)
• HbA1c value ≥ 7.0% (53 mmol/mol)
• BMI ≥ 23 kg/m2
• Consent to participate
• Sufficient knowledge of the German language

Exclusion criteria

• diagnosis of type 1 diabetes mellitus (T1DM)
• change in medication, frequency of use or dosage (planned within 4 weeks before T0 or during the study period)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

0 participants in 2 patient groups

online intervention in addition to treatment-as-usual

Experimental group

Description:

online intervention: covivio in addition to treatment as usual

Treatment:

Behavioral: covivio (additional to treatment as usual)

treatment-as-usual

Other group

Description:

Other: treatment as usual

Treatment:

Other: treatment as usual